Foster et al.

1 Tumour-intrinsic features shape T-cell differentiation through 2 myeloma disease evolution

3

4 Kane A. Foster¹, Elise Rees¹, Louise Ainley^{1,2}, Eileen M. Boyle^{1,2}, Lydia Lee^{1,2}, Gwennan Ward¹,

5 Daria Galas-Filipowicz¹, Anna Mikolajczak¹, Emma J. Lyon¹, Dylan Jankovic¹, Jasmine

- 6 Rahman¹, Mahima Turakhia¹, Imran Uddin^{3,4}, Gordon Beattie^{3,4}, Yvette Hoade¹, Catherine
- 7 Zhu^{1,2}, James L. Reading^{5,6}, leuan Walker^{7,8}, Michael Chapman^{7,8} Karthik Ramasamy⁹, Javier

8 Herrero¹⁰, Benny Chain^{11,12}, Sergio A. Quezada^{6,13}, Kwee L. Yong^{1,2}

- 9
- ¹Research Department of Haematology, University College London Cancer Institute, London, United Kingdom.
- ²University College London Hospitals NHS Foundation Trust, London, United Kingdom.
- 12 ³CRUK City of London Centre Single Cell Genomics Facility, UCL Cancer Institute, University College London,
- 13 London, UK.
- 14 ⁴Genomics Translational Technology Platform, UCL Cancer Institute, University College London, London, UK.
- 15 ⁵Pre-Cancer Immunology Laboratory, UCL Cancer Institute, London, UK.
- 16 ⁶Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, UK.
- 17 ⁷MRC Toxicology Unit, Cambridge, United Kingdom.
- 18 Cambridge University Hospitals NHS Trust, Cambridge, United Kingdom.
- 19 ⁹Oxford University Hospitals, NHS Foundation Trust, Oxford, UK.
- 20 ¹⁰Bill Lyons Informatics Centre, University College London Cancer Institute, London, United Kingdom.
- 21 ¹¹Division of Infection and Immunity, University College London, London, UK.
- 22 ¹²Department of Computer Sciences, University College London, London, UK.
- 23 ¹³Immune Regulation and Tumour Immunotherapy group, Cancer Immunology Unit, Research Department of
- 24 Haematology, University College London Cancer Institute.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Foster et al.

25 Abstract

26

The haematological malignancy multiple myeloma is associated with skewed T-cell activation 27 28 and function. T-cell alterations are detectable in asymptomatic myeloma precursor conditions and have the potential to identify precursor patients at imminent risk of 29 30 progression. However. what myeloma-associated T-cells alterations represent 31 mechanistically, how they relate to tumour burden and gene expression, and what influences 32 high inter-patient variability in immune composition remains unknown. Here, we assembled 33 the largest ever dataset of published and newly-generated single-cell RNA and TCR sequencing of the marrow and blood from patients with myeloma, precursor conditions, and 34 35 age-matched non-cancer controls. We show myeloma is not associated with T-cell exhaustion and instead defined by a pattern of T-cell differentiation resembling antigen-36 37 driven terminal memory differentiation. Myeloma-associated T-cell differentiation was 38 dependent on tumour-intrinsic features including tumour burden and tumour expression of antigen-presentation genes. Expanded TCR clones accumulating in myeloma were not 39 40 enriched for viral specificity and were detected in effector states in highly infiltrated marrows. 41 Together, these results suggest anti-tumour immunity drives a novel form of cancer-42 associated T-cell memory differentiation in myeloma.

Foster et al.

44 Introduction

45

46 T-cells are polyfunctional immune cells and fundamental players in anti-tumour immunity¹. In 47 solid cancers, evidence suggests early in carcinogenesis tumour growth can be curtailed by 48 tumour-reactive T-cells^{1,2}. However, persistent activation drives these cells away from 49 functional memory states towards a hypo-responsive state of terminal differentiation termed 50 exhaustion^{3,4}, characterised by the expression of immune checkpoint molecules like 51 programmed cell death protein 1 (PD1)⁵, contributing to cancer progression in solid cancers. 52 This complex interaction is believed to shape tumours from the early precursor stages to 53 relapsed and refractory disease¹. Understanding these insights have refined the treatment of 54 solid tumours through the development of immunotherapies targeting exhausted T-cells⁶.

55

56 Multiple myeloma (MM) is a haematological malignancy of bone marrow (BM) plasma cells 57 that is largely incurable^{7,8}. Two precursor conditions of increasing severity precede MM: 58 Monoclonal Gammopathy of Undetermined Significance (MGUS) and then Smouldering 59 Multiple Myeloma (SMM). They differ in their risk of progression to overt myeloma with MGUS 60 and SMM being associated with a 5-year progression rate of approximately 7% and 50% 61 respectively⁹. While not every MGUS or SMM patient will progress, virtually every MM patient has transitioned through these stages¹⁰. Thus, there is a pressing clinical need to identify 62 63 asymptomatic patients with precursor conditions at imminent risk of progression. Current risk 64 factors rely largely on tumour bulk¹¹, namely the levels of plasma cell infiltration in the bone 65 marrow and serum concentrations of paraprotein (malignant cell-derived clonal 66 immunoglobulin) and beta-2 microglobulin (B2m)⁹. However, the role of the BM tumour 67 microenvironment, particularly T-cells, in progression remains poorly understood. 68 Understanding how myeloma drives alterations in T cell state and function is complicated by 69 the influence of patient advanced age and marrow homeostatic T-cell differentiation^{7,12,13}.

Foster et al.

This, together with high inter-individual immune heterogeneity, confounds identifying
associations between T-cells and tumour biology or progression.

72

73 To solve this, we combined over a million single cells from 295 samples from 237 donors 74 using newly-generated single-cell RNA sequencing (scRNA-seq) and T-cell receptor (TCR) 75 sequencing (scTCR-seq) data and 11 published studies^{14,15,24,16-23}, allowing us to interrogate T-cell dynamics while controlling for natural and tumour-associated sources of inter-76 77 individual variation. We show for the first time that the T-cell landscape associated with 78 myeloma possess features of antigen-driven terminal memory differentiation and highlight 79 the features of tumour biology driving this. These results suggest that anti-tumour immunity 80 underpins a novel form of tumour-associated T-cell differentiation in myeloma.

81

- 82 Results
- 83

84 Effective integration of scRNA-seq datasets allows a detailed classification of immune cell
85 populations

86

87 To study immune differentiation through myeloma disease evolution we generated a large 88 scRNA-seq map of BM and peripheral blood (PB) cells from untreated MGUS (n = 20, 9%), 89 SMM (n = 58, 25%) and MM (n = 54, 23%) patients alongside non-cancer controls (n = 102, 44%; Fig. 1a, Extended Data Fig. 1a, Supplemental Table 1). Patients were older than 90 91 controls (controls median 55 range 21-87, MGUS median 62 range: 41-81, SMM median 62 range: 29-81, MM median 62 range: 38-77; Fig. 1b). As expected, plasma cell infiltration of 92 93 the bone marrow and serum paraprotein levels rose with from SMM to MM (infiltration P =94 0.001, paraprotein P < 0.05, Wilcoxon test; Fig. 1c).



Fig. 1 | **Single cell phenotypes are harmonized in a l and non-cancer controls. a**, Schematic depicting the included in the study. **b**, Box plot showing the distributi 53) patients. **c**, Box plots showing the distribution of rated scRNAseq dataset of patients with myeloma and precursor conditions ssue types (BM, bone marrow; PB, peripheral blood), and singe-cell data types years) in non-cancer controls (n = 86), MGUS (n = 20), SMM (n = 58) and MM (n = CD138+ (left) and paraprotein values (right) in SMM (n = 13) and MM (n = 19)

patients. **d**, Visualisation of all cells in the dataset by unhour manifold approximation and projection (UMAP). The colour each point (cell) represents the indicated cell type cluster. The percentage of all cells occupied by each cluster is inset. **e**, Bar chart showing the proportion of each cluster for each individual donor (columns) for each cohort. **f**, UMAP as in (**d**) separated by cohort (columns) and tissue type (rows). The number of donors and cells for each separation is inset. **g**. Bar chart showing the proportion of plasma cells with clonal or non-clonal immunoglobulin usage. Plasma cells with clonal immunoglobulin usage were classified as tumour cells. **h**. Pie chart quantify the proportion of each pan-cancer transcriptional pathway which was the most highly expressed (dominant) in tumour cells across all patients. **i**, Dot plot showing FDR-adjusted *P* values and correlation coefficients between cell type cluster abundance (as a proportion of non-plasma cells) and pan-cancer transcriptional pathway expression in tumour cells (n = 45 patients). Box plots represent the first and third quartiles around the median with whiskers extending 1.5 times the interquartile range. *P* values shown on box plots were calculated by two-sided Wilcoxon test.

Foster et al.

96 Following quality control and correcting for batch effects (see Methods), Extended Data Fig. 97 1b), cells were clustered to 9 major cell types and phenotyped using RNA expression, protein 98 expression via cellular indexing of transcriptomes and epitopes (CITE-seq), and de novo label 99 prediction tools (Fig.1d, Extended Data Fig. 1c,d). T-cells (defined by co-expression of CD3D, 100 CD3E, CD3G, CD8A and CD4 RNA and CD3 protein) comprised roughly half (50.2%) the cells 101 in the dataset (Fig. 1e), with another guarter occupied by similar proportions of myeloid cells 102 (FCN1+FCER1G+CD14+; 15%) and haematogenic progenitors (CD34+MPO+TYMS+; 11%). 103 The remainder of the dataset was comprised of equivalent numbers of NK cells 104 (KLRD1+FCG3RA+CD56+; 8%), B cells (CD79A+CD19+; 7.5%), and plasma cells 105 (MZB1+SDC1+; 6.6%), alongside small (<1% total counts) clusters of neutrophils 106 (NEAT1+NAMPT+), non-haemopoietic cells (CXCL12+COL3A+), and platelets (PPBP+PF4+).

107

108 Despite the heterologous sorting strategies employed by different studies (Extended Data 109 Fig. 1b), we identified major determinants of cellular composition in our dataset (Fig. 1f). 110 Plasma cells and progenitors were enriched in the BM relative to PB (P < 0.001 and P < 0.001, 111 respectively. Wilcoxon test), suggesting a relative lack of haemodilution in BM aspirates. As 112 expected, plasma cells were most highly enriched in the BM of patients relative to controls 113 (P < 0.001, Wilcoxon test). However, the global distribution of cell types was otherwise similar 114 in diseased and controls marrows, suggesting progression to myeloma may be associated 115 with more granular alterations to immune composition.

116

Overall, we analysed 1,009,317 cells from 234 individuals with RNA and clinical data, 109 with TCR and 1 with CITE-seq data, including 224 BM and 71 PB samples. This resource represents a large cross-sectional analysis of controls and myeloma disease stages and reliably discriminate key immune phenotypes of non-cancer controls and myeloma patients through disease evolution.

Foster et al.

122

123 Recurrent transcriptional pathways in malignant plasma cells underpin progression and 124 outcome

125

126 Next, we sought to characterise more granular features associated with disease evolution 127 that may reveal tumour-immune cross-talk by conducting an analysis of tumour cells. 128 Malignant clones, identified by clonal immunoglobulin usage (see Methods; Extended Data 129 Fig. 2a-c), composed the majority of plasma cells in all patients but were most abundant in 130 MM (Fig. 1g and Extended Data Fig. 2f). To overcome inter-patient tumour transcriptional 131 heterogeneity we scored 67,656 plasma cells from 46 patients with a recently published set of pan-cancer transcriptional pathways²⁵ (Extended Data Fig.2e, Supplemental Table 2). The 132 133 pathway most highly expressed by tumour cells corresponded to the unfolded protein 134 response (67% tumour cells, Fig. 1h), with the remaining cells defined by pathways reflecting 135 cellular stress, respiration, or other biological processes.

136

To explore the significance of these pathways in disease evolution, we compared their 137 138 expression in SMM (n = 17) and MM (n = 29; Extended Data Fig. 2f-g), analysed associations 139 with local marrow infiltration (Extended Data Fig. 2h), and overall survival in MM patients from the CoMMpass study²⁶ (Extended Data Fig. 2i). We identified 18 pathways significantly 140 141 associated with progression or marrow infiltration, of which 6 were associated with outcome. Broadly, pathways reflecting proteostasis such as the unfolded protein response were 142 characteristic of SMM (P < 0.001, Wilcoxon test), whereas more functionally diverse set of 143 144 pathways were enriched at progression (Extended Data Fig. 2f-g). Proliferation pathways were enriched at progression (P = 0.07, Wilcoxon test), in highly infiltrated marrows (R = 0.42, 145 146 P = 0.03, Pearson correlation), and associated with significantly shorter overall survival (P <147 0.001, log-rank test; Extended Data Fig. 2i). Conversely, a SMM-enriched pathway

Foster et al.

characterised by immunoglobulin genes was more frequently highly-expressed in lessinfiltrated marrows and association with more favourable outcome (P < 0.001, log-rank test). This suggests plasma cells retaining normal functions, such as proteostasis²⁷, were more common in low risk-and low burden disease, whereas more proliferative states are associated with worse outcome.

153

154 Cellular stress was among the pathways more frequently expressed in MM (P = 0.007, 155 Wilcoxon test; Extended Data Fig. 2e). We extricated this pathway from in vitro stressors 156 such as those introduced by sample processing (Extended Data Fig. 2j). Closer inspection of 157 tumour cells highly expressing the stress pathway revealed an enrichment of genes also associated with cell death (P = 0.02, GSEA of programmed cell death pathway: Extended 158 159 Data Fig. 2k). Death pathways were enriched at progression and positively correlated with 160 tumour burden (Extended Data Fig. 2k, Supplemental Table 2), suggesting this stress 161 pathway may reflect death-associated processes. Despite an enrichment at progression, 162 high expression of the stress pathway was associated with superior outcome (P = 0.014, log-163 rank test; Extended Data Fig. 2i), suggesting a more complex relationship for this pathway 164 through disease evolution possibly related to immune correlates.

165

Finally, we compared tumour pathways with immune composition. Tumour cell pathway expression was not associated with the abundance (as a fraction of non-plasma cells) of cell types in the BM (all individual cell type-tumour pathway correlations adjusted P > 0.05, Pearson correlation; Fig. 1i).

170

Together, this data show how the transcriptional activity of tumour cells is influenced related
to progression, infiltration, and outcome. However, connecting these pathways to tumour–
immune interactions may require a more granular overview of immune cells.

Foster et al.

174

175 In-depth T-cell phenotyping reveals myeloma is not enriched in exhausted cells and T-cell
176 composition is similar in health and disease

177

To more deeply probe immune perturbations and tumour-immune cross-talk in disease 178 179 evolution, T-cells were isolated, re-integrated and re-clustered to 19 discrete phenotypes and transcriptional states based on expression of canonical RNA and protein markers (Fig. 2a-b, 180 Extended Data Fig.3a-c, Supplemental Tables 2-3)^{4,28-30}. CD4+ cells were predominantly 181 naïve (Tn, 49% of CD4+T-cells) and central memory (Tcm, 21%) cells, and the remainder in 182 regulatory (Treg, 8.4%), helper (Th17 7.2%; T effector memory, Tem 6.1%) or cytotoxic 183 (cytotoxic T lymphocyte, CTL, 8.7%) states. CD8+ cells were classified into a more linear 184 185 trajectory spanning earlier Tn (20% of CD8+T-cells), Tcm (4.6%) and IL7R-expressing 186 effector memory (Tem.IL7R, 12%) through PDCD1+ activated Tem (TemActive, 22%) to more 187 later differentiated GZMB+ terminal Tem (TemTerm, 18%) and Tem re-expressing CD45RA 188 (TEMRA, 15.1%) subsets, alongside tissue resident (Trm, 5.1%) and exhausted (Tex, 0.7%) clusters. Invariant subsets, comprising vo T-cells (gdT) and mucosal-associated invariant T-189 190 cells (MAIT), proliferating and interferon-induced clusters were also identified. This included 191 an interferon-induced cluster resembling effector T-cells characterised by expression of IFN-192 induced protein with tetratricopeptide repeats 2 (IFIT2) alongside effector molecules TNF and 193 IFNG (Teff.IFIT2). This functional annotation was consistent with patterns of TCR expansion 194 (Fig. 2c, Extended Data Fig. 3d-e), with the most clonally expanded clusters expressing the 195 highest level of late differentiation markers. Our phenotypes showed high concordance with 196 published and predicted cluster labels (Extended Data Fig. 3f), arguing for a faithful 197 representation of T-cell phenotypes in our integrated dataset.

198



Fig. 2 | **The T cell landscape of myeloma is not enriched in exhausted cells and reflects intrinsic marrow biology. a**, Visualisation of all T cells in the dataset by minimum-distortion embedding (MDE). The colour each point (cell) represents the T cell cluster indicated by the legend. Pie charts depict the percentage of CD4+ (left) and CD8+ (right) T cell clusters in the dataset. b, MDE plots showing the expression of *CD4*, *CD8A*, and naïve and cytotoxic genes signatures. **c**, Left, MDE plot showing the clonal expansion of T cell receptor (TCR) clones (calculated as the number of times a unique clone was seen). Right, Bar chart showing the proportion of each CD8+ (left) and CD4+ (right) cluster among TCR clones of the indicated size. Bar colour represents T cell cluster indicated in (**a**). **d**, Box plots showing the expression (top) and bar plots showing the percentage of cells expressing (bottom, fraction of cells with non-zero expression) indicated T cell exhaustion associated genes in CD8.Tex, CD8.TemActive and other CD8+ T cell clusters. For the three groups a random sample of 1,000 cells from Zheng et al. are shown. *P* values calculated by Wilcoxon test, ** = *P* < 0.001, * = *P* < 0.01, NS = *P* > 0.05. **e**, Bar plot showing the abundance of CD8.Tex as a percentage of total CD8+ T cells for the twenty donors with the highest abundance of CD8.Tex. **f**, MDE as in (**a**) separated by cohort (columns) and tissue (rows: bone marrow, BM; peripheral blood, PB). For the four groups a random sample of 20,000 cells is shown. The total number of cells for each separation is inset. The CD8.TemActive cluster is circled. **g**, Box plot showing the abundance of CD8.TemActive as a percentage of T cells in the PB and BM of non-cancer controls (Non, PB n = 39, BM n = 73; left) and SMM and MM patients (Cancer, PB n = 30, BM n = 123; right). Box plots were calculated by two-sided Wilcoxon test.

Foster et al.

We validated our proposed BM T-cell landscape by employing CyTOF on an independent cohort of 9 SMM and 11 MM donors, assaying 940,000 cells with 46 markers (Supplemental Table 4). *De novo* clustering and a comparison of T-cell clusters across technologies (see Methods) revealed a range of phenotypes closely matched and enhanced those seen in our scRNA-seq dataset (Extended Data Fig. 4). For example, expression of the CD57 glycoepitope on GZMB+ CD28– CD8+Tem (CD8.Tem-Term) suggested a phenotype of terminal effector memory cells^{31,32}.

206

207 We identified exhausted CD8.Tex by the expression of high levels of PDCD1 and TIGIT, alongside other RNA markers of exhaustion like CXCL13 and LAYN²⁹. Importantly, we 208 209 distinguish CD8.Tex from GZMK-expressing CD8.TemActive. CD8.TemActive expressed 210 higher PDCD1 and TOX than non-exhausted bone marrow T-cells (P < 0.001 and P < 0.001, 211 Wilcoxon test) but less than CD8.Tex (P < 0.001 and P < 0.001, Wilcoxon test) and lacked 212 other markers of exhaustion like LAYN (P < 0.001, Wilcoxon test; Fig. 2d, Extended Data Fig. 213 3b) and expressed early differentiation markers like CD28. In our CyTOF dataset, expression of PD1 and the exhausted-associated transcription factor TOX³³ were similarly restricted to 214 215 early CD8+Tem (CD45RO+KLRG1+CD28+; Extended Data Fig. 4c). Interestingly, the 216 CD8.Tex cluster was almost entirely composed of cells from a single myeloma patient (1181 217 of 1222 cells, 97%; Fig. 2e) who contributed the majority of exhaustion marker-expressing 218 cells (Extended Data Fig. 2g), suggesting CD8.Tex were a donor-specific phenomenon. 219 Similar observations were made for the CD8.Trm cluster, being mostly composed of 2 220 samples from the same study as the donors-specific CD8.Tex (27.4% and 26.1% of cells; 221 Extended Data Fig. 5a). These data lead us to suggest that exhausted T-cells are rarely seen 222 in myeloma and the more frequent PD1-expressing activated CD8+Tem are distinct from 223 exhausted cells.

224

Foster et al.

Similar T-cell phenotypes were observed in the BM and PB (Fig. 2f), but the proportion of Tcell clusters differed between tissues (Extended Data Fig. 3h). Notably, CD8.TemActive were enriched in the BM of both patients and controls (P < 0.001 and P < 0.001, Fig. 2g), suggesting intrinsic marrow biology regulates the abundance of this subsets in health and myeloma.

230

T-cell differentiation skewing occurs in disease independent of age and presents similarly in
 pre-malignant SMM and overt MM

233

234 We next asked how the relative abundance of T-cell subsets in the BM was altered across 235 disease stages. BM T-cell composition was strikingly similar in patients and controls (Fig. 3a, 236 Extended Data Fig. 5a), with the exception of donor-specific CD8.Tex clusters. We next 237 compared the T-cell composition of controls with each myeloma disease stage in turn, 238 statistically controlling for age. The most prominent difference in BM T-cell composition 239 between health and disease was the loss of naïve, CD4.Th17 and MAIT cells and an 240 enrichment of *GZMB*-expressing memory T-cell clusters (FDR-adjusted *P* < 0.1 for all, linear 241 models; Fig. 3b, Extended Data Fig. 5b). When removing the one patient who contributed the 242 majority of CD8.Tex cells (97% cells; Fig. 2e), this cluster was not enriched in MM relative to 243 controls (P = 0.54, linear models). As non-cancer controls included hip replacement and 244 deceased donors, we repeated our analysis with only healthy donors and obtained the same 245 results (Extended Data Fig. 5c). Low-risk MGUS possessed a T-cell composition with the 246 fewest differences to control marrows. Conversely, T-cell composition was similar between 247 the higher-risk but pre-cancerous SMM and symptomatic MM (Extended Data Fig. 5d). While 248 the normalised abundance of CD8.Tex was lower in SMM than MM independent of age (P < 249 0.001, linear model), in terms of unnormalized counts this only represented 8 MM patients 250 with a median of 1 CD8.Tex cells each suggesting this did not represent a meaningful

medRxiv preprint doi: https://doi.org/10.1101/2024.06.22.24309250; this version posted July 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.



+ marrow T cell composition occur through myeloma disease evolution. a, Visualisation of BM T cells

by minimum-distortion embedding (MDE) in non-cancer controls (Non), MGUS, SMM and MM patients. For the four groups a random sample of 20,000 cells is shown. b, Box plots showing the normalised abundance (see Methods) of CD8.Tn (left) and CD8.TemTerm (right) in the BM as a percentage of T cells in non-cancer controls (n = 71), MGUS (n = 16), SMM (n = 48) and MM (n = 41) patients. c, Left, Box plot showing the value of the T cell skewing (the first principal component (PC1), 24.27% variance, calculated on BM samples only) in Non (n = 68), MGUS (n = 16), SMM (n = 45) and MM (n = 39) patients. Right, representation of the clusters with the highest and lowest contribution (loading) to PC1. For example, a high PC1 value corresponds to a high number of CD8.TemTerm. d, Forest plot showing the relationship between T cell skewing and disease stage (MGUS (n = 16), SMM (n = 44) and MM (n = 37) relative to controls (n = 53)) and age (binarized to \geq median age (60 years)). Coefficients with 90% confident interval (CI) and P values from linear model (see Methods) are inset. e, Dot plot showing the correlation between T cell skewing and age in non-cancer controls and MM patients. P value from linear model is inset. f, Box plot showing exaggerated T cell aging (the residuals between a patient's PC1 values and a model of PC1 and age in controls only, see Methods) in MGUS, SMM and MM patients. Residuals of zero (T cell skewing expected for patient's age) is indicated with dashed line. g, Dot plots showing the correlation between the abundance of CD8.TemTerm (left) and T cell skewing (right) in the PB and BM for patients with samples from both tissues. h, Upper, Schematic depicting longitudinal sampling of patient 58408 from Liu et al. Lower, Bar plot showing the abundance of indicated T cell cluster in SMM and MM for patient 58408. Box plots represent the first and third quartiles around the median with whiskers extending 1.5 times the interquartile range. P values shown on box plots were calculated by two-sided Wilcoxon test. R and P values for correlations were calculated by Pearson correlation. Correlation shaded regions represent the 95% confidence interval of linear regression slopes.

Foster et al.

enrichment. For patients with available risk data, we saw no significant differences in T-cell composition between international staging system (ISS) and SMM Mayo risk groups^{9,34} (Extended Data Fig. 5e). In our smaller CyTOF cohort we noted a trend for the enrichment of CD57+ CD8.Tem-Term in MM relative to SMM (Extended Data Fig. 5f). These results suggest that smouldering and overt myeloma are associated with similar T-cell alterations independent of age.

257

258 To interrogate changes to BM T-cells in a less supervised manner we ran principal 259 component analysis (PCA) on patient's T-cell composition. The first principal component explaining the highest fraction of variance in T-cell composition (PC1, 24.27%; Extended 260 261 Data Fig. 5g) described a compositional shift across clusters from more naïve and early subsets to terminal memory clusters (Fig. 3c). As this composition alteration represented a 262 shift from phenotypes at either end of the T-cell differentiation spectrum⁴, we termed PC1 263 264 "T-cell skewing". T-cell skewing was highest (indicating an enrichment of terminal memory 265 clusters) in SMM and MM relative to controls independent of age (P < 0.004 and P < 0.001, 266 respectively, linear model; Fig. 3c-d), demonstrating this metric captured the major 267 alterations to T-cells in myeloma. We noted T-cell skewing was associated with age 268 independent of patient group (P = 0.013, linear model, R = 0.28, Pearson correlation; Fig. 3d, Extended Data Fig. 5h) and correlated with age in controls (P < 0.05, R = 0.25; Fig. 3e). As T-269 270 cell skewing was independently associated with both myeloma and age (Fig. 3d), this 271 component of myeloma-associated T-cell differentiation resembled T-cell alterations seen 272 during aging. Therefore, patients possessed an exaggerated form of the T-cell compositional 273 skewing seen with aging. The degree of exaggerated T-cell aging (see Methods) trended to 274 rise with disease severity (MGUS versus MM, P = 0.06, Wilcoxon test; Fig. 3f) and the highest 275 fraction of patients with exaggerated skewing was seen in myeloma (86%) versus MGUS 276 (68%) and SMM (72%).

Foster et al.

277

278 PC1 values and the abundance of terminal memory subsets in the BM strongly correlated in 279 the PB of the same patients (Fig. 3g), further indicating a similarity of these changes to 280 systemic T-cell alterations seen with aging¹².

281

Finally, in a single patient sampled longitudinally at SMM and at progression to MM we observed the same compositional alternations seen cross-sectionally (Fig. 3h), suggesting these differentiated T-cell phenotypes accumulate longitudinal within patients through disease evolution.

286

287 Features of antigen-specific responses underpin myeloma-associated T-cell differentiation

288

289 Next, we analysed features of the TCR repertoire. Repertoire clonality was associated with T-cell skewing in patients independent of age (P < 0.001, linear model, R = 0.71; Fig. 4a). We 290 291 observed similar results when restricting analysis to CD8-expressing memory clones (P <292 0.01, linear model, R = 0.55; Fig. 4a, Extended Data Fig. 6a), with both the clonality and the 293 abundance of expanded clones of this subset was trending for enrichment in MM relative to 294 controls (Fig. 4b). T-cell skewing and CD8+ memory diversity did not correlate in controls (P = 0.66, linear model; Extended Data Fig. 6b), suggesting enhanced clonal expansion may be 295 296 a unique feature T-cell differentiation in myeloma.

297

The accumulation of TCRs possessing similar CDR3 sequences can indicate responses against shared antigens³⁵. Using tcrdist3³⁶ we grouped all expanded TCRs in the dataset (11,545 clones) into 279 clusters (composed of 1,014 clones, 8.8% of input; Extended Data Fig. 6c-d, Fig. 4c). This analysis revealed an increasingly large fraction of the TCR repertoire was occupied by clustered clones in MM (median 8.7% range 3-35) relative to SMM (median





Fig.4 | Features of antigen-experienced T cell receptor repertoires underpin myeloma-associated T cell differentiation. a, Dot plots showing the correlation between T cell skewing (PC1 values) and TCR clonality (log₁₀ 1/Simpson's diversity) among all T cell clones (left) and CD8+ memory clones (CD8+ clones, CD8+ clusters excluding CD8.Tn and CD8.Tcm) in MGUS, SMM and MM patients (all T cell clones n = 42, CD8+ memory clones n = 29). b, Box plots showing the clonality (left) and abundance of expanded clones (right) of CD8+ memory clones in non-cancer controls (n = 15), SMM (n = 19) and MM (n = 12). c, Network plots showing the extent of clustering among expanded (>1) TCRs from two representative patients with low (left) and high (right) percentages of total repertoire clustering. Each node represents a TCR clone and each edge that two TCR clones had a co-clustered alpha or beta sequence. An asterisk indicates a cluster analysed in e. d, Left, Box plot showing the percentage of clustered expanded TCRs in SMM (n = 19) and MM (n = 15). Right, dot plot showing the correlation between PC1 values and the the percentage of clustered expanded TCRs in MGUS, SMM and MM patients (n = 35). e, Left, Dot plot showing the correlation of T cell skewing and the percentage of CD8+Tem (CD8.TemTerm, CD8,TEMRA) among cells from clustered TCR clones. f, Results from a differential expression analysis of T cells possessing TCR clones annotated as viral-reactive (see Methods) versus all other clones. Expression testing was performed in 19 patients with a median of 20 viral-reactive and 966 unannotated clones per-patient. The 10 most highly non-viral enriched genes were used to define a non-viral specificity signature and are labelled. g, Visualisation of 1,016,900 T cells by minimum-distortion embedding (MDE). The colour each point (cell) represents the non-viral specificity signature score expressed by that T cell. h, Dot plots showing the correlation between the mean non-viral specificity signature score per-patient and T cell skewing, the percentage of clustered TCRs among expanded TCRs, and TCR clonality in MGUS, SMM and MM patients. i, Box plot showing the mean non-viral specificity signature score in MGUS (n = 16), SMM (n = 45) and MM (n = 40) patients. Box plots represent the first and third quartiles around the median with whiskers extending 1.5 times the interquartile range. P values shown on box plots were calculated by two-sided Wilcoxon test. R and P values for correlations were calculated by Pearson correlation. Correlation shaded regions represent the 95% confidence interval of linear regression slopes.

Foster et al.

303 3.1% range 0-11.3) and this fraction correlated with T-cell skewing (R = 0.4, P = 0.02, Pearson 304 correlation; Fig. 4d). T-cell skewing was specifically associated with the clustering of *GZMB*-305 expressing CD8+ memory cells (R = 0.47, P = < 0.01; Fig. 4e), suggesting conserved antigen-306 specific responses drive T-cell differentiation in myeloma, specifically among *GZMB*-307 expressing subsets.

308

309 We next explored the T-cell antigen specificity. TCR specificity databases are mostly composed of viral antigens³⁷⁻³⁹, allowing us to ask if viral antigen specificities were involved 310 311 in T-cell differentiation and clonality in myeloma (see Methods). In 19 patients we identified 312 putative HLA-matched specificities for a median of 7 (range 2-88) paired clone per-patient 313 against viral antigens (Extended Data Fig. 6e). Comparing gene expression between clones 314 with and without putative viral-specificity annotations, we observed clones predicted to be 315 non-viral specific expressed genes characteristic of terminal memory such as GZMB, 316 perforin/PRF1 and Hobit/ZNF683 (Fig. 4f, Supplemental Table 5). We summarised the 317 expression of these genes into a non-viral specificity gene signature (Extended Data Fig. 6f). 318 Non-viral specificity mapped to GZMB+ terminal memory clusters (Fig. 4g, Extended Data 319 Fig. 6g), correlated with T-cell skewing, clonality and repertoire clustering (Fig. 4h), and was 320 enriched in MM relative to precursor conditions (Fig. 4i). Together, these data show myeloma-321 associated T-cell differentiation occurs alongside alterations to the TCR repertoire 322 resembling antigen-direct T-cell immunity which may not reflect the activity of viral-specific 323 TCR clones.

324

325 Tumour-intrinsic features drive two clonally-related patterns of T-cell differentiation

326

327 We next asked if features of tumour biology may drive T-cell skewing. We examined serum 328 paraprotein and B2m concentrations, plasma cell marrow infiltration, and tumour cell

Foster et al.

transcriptional state (Extended Data Fig. 2). As T-cell skewing overlapped in precursor
 patients and overt MM (Fig. 3c), we looked for associations among all patients independent
 of disease stage.

332

We did not find an association between T-cell skewing and tumour transcriptional state, 333 334 marrow infiltration, or B2m levels (Fig. 5a, Extended Data Fig. 7a-b). However, we observed a positive correlation between high T-cell skewing and an enrichment of terminal memory 335 336 cells with paraprotein levels (R = 0.45, P = 0.02, Pearson correlation; Fig. 5a-b, Extend Data 337 Fig. 7c). This association was seen across different disease stage and centres (Extended Data Fig. 7d) and was recapitulated in our CyTOF cohort (Extended Data Fig. 7e). The same 338 paraprotein correlation was also seen with TCR repertoire clonality (R = 0.53, P < 0.001, 339 340 Pearson correlation; Fig. 5a, Extended Data. 7f). We found the degree of exaggerated T-cell 341 aging was significantly higher in SMM and MM patients with high paraprotein levels 342 independent of disease stage (P = 0.01, linear model; Extended Data Fig. 7g), suggesting 343 paraprotein was the main driver of T-cell skewing in patients.

344

345 We speculated tumour-intrinsic features were associated with individual T-cells clusters 346 independent of overall T-cell skewing. Analysis of T-cell cluster abundance with marrow 347 infiltration and transcriptional pathway scores in tumour cells revealed effector-like Teff.IFIT2 348 cells were enriched in highly-infiltrated marrows populated by stressed tumour cells (marrow infiltration: R = 0.55, tumour stress: R = 0.6; Fig. 5a-b, Extended Data Fig. 7h-i). Several other 349 350 clusters possessed a significant correlation with tumour stress, including positive and 351 negative associations with CD8.Trm and CD4.Tem, respectively (Extended Data Fig. 7i). Teff.IFIT2 cells were not uniquely defined by stress-associated genes (P = 0.12, GSEA of 352 353 stress pathway among Teff.IFIT2 marker genes), arguing against this association 354 representing exposure to similar stressors across T and tumour cells. Additionally, the



Fig. 5 | Tumour-intrinsic drivers of T cell differentiation indicate anti-tumour immunity contributes to myeloma-associated T cell differentiation. a, Heatmap showing the correlation between tumour-intrinsic features (rows) and T cell features (columns) in all patients. Cell colour represents strength of association (correlation) and asterisk degree of significance (Pearson correlation). b, Dot plot showing the correlation between T cell skewing (PC1) and paraprotein values (left) and the normalised abundance (see Methods) of Teff.IFIT2 and the aspirate % CD138+ (right). c, Left, correlation between the average expression the twenty most significant CD8.TEMRA marker genes among Teff.IFIT2 cells and the the abundance of cancer cells highly expressing stress pathway genes. Right, Box plot showing the median expression of the CD8.TEMRA marker gene score per-clone among cells in the Teff.IFIT2 cluster. Each clone was grouped based on the T cell cluster composition of the remaining cells that composed that clone, specifically the abundance of GZMB-expressing Tem clusters (CD8.TEMRA, CD8.TemTerm and CD4.CTL), classifying those which were >50% composed of GZMB-expressing clusters as Shared and that those which were not as Unshared. d, Bar plot showing the T cell cluster composition of the largest CD8+ clones expanded in the Teff.IFIT2 cluster in three representative myeloma patients. Expanded Teff.IFIT2 clones are predominantly in GZMB+Tem (CD8.TEMRA, CD8.TemTerm and CD4.CTL) clusters. e, Left, Visualisation of T cells by minimum-distortion embedding (MDE). The coloured points (cell) represents cells derived from TCR clones predicted as reactive against cancer cell-expressing neoantigens (pNeoAg-reactive, see Methods). Point colour reflects individual clones. Right, Box plot showing the median expression of the non-viral specificity signature in expanded clones annotated as either pNeoAg-reactive or with no annotation. f, Heatmap showing the expression of genes significantly up- and down-regulated on cancer cells relative to non-cancer plasma cells across patients. Patients were classified as "MHC high" if their tumour cells had significantly upregulated the antigen processing and presentation pathway relative to nontumour cells and as "MHC low" if not. g, Box plot showing the expression of the non-viral specificity signature in patients with high and low expression of MHC genes (f). h, Kaplan-Meier curve showing the impact of high (red) and low (blue) scoring of the MHC pathway (f) on overall survival in 598 newly-diagnosed untreated multiple myeloma patients enrolled in the ComMMpass trial. P value calculated using log-rank test. i, schematic representing a summary of findings. Box plots represent the first and third quartiles around the median with whiskers extending 1.5 times the interquartile range. P values shown on box plots were calculated by two-sided Wilcoxon test. R and P values for correlations were calculated by Pearson correlation. Correlation shaded regions represent the 95% confidence interval of linear regression slopes.

expression of a smaller set of T-cell effector genes (*CD69*, *TNF*, *IFNG*) followed the same correlations (marrow infiltration: R = 0.43, tumour stress: R = 0.79, Pearson correlation; Fig.5a, Extended Data Fig. 7j), suggesting a T-cell effector program specifically was associated with infiltration and tumour stress.

359

360 Concurrent tumour-associated T-cell memory and effector differentiation suggests a differentiation process between these two states. Clonally expanded Teff.IFIT2 cells enriched 361 362 in highly-infiltrated marrows populated by stressed tumours expressed markers characteristic of GZMB-expressing CD8.TEMRA (Fig. 5c, Extended Data Fig. 7k). This 363 364 expression was attributable to cells derived from GZMB-expressing CD8+ terminal memory 365 clones (Fig. 5c) and clonally expanded Teff.IFIT2 clones predominantly in these GZMB+ 366 phenotypes (Fig. 5d, Extended Data Fig. 7k). Therefore, terminally differentiated memory 367 clones accumulating in myeloma are continuous with effector-like T-cells in infiltrated 368 marrows, suggesting these states are linked by a T-cell differentiation pathway.

369

370 Myeloma-associated T-cell differentiation possesses features of anti-tumour immunity

371

372 The enrichment of clonal memory T-cells independent of age and viral specificity in myeloma 373 suggests tumour-directed T-cell responses. To investigate this, we identified TCR predicted 374 to bind autologous tumour neoantigens in two patients (see Methods). Expanded TCRs 375 predicted to bind neoantigens mapped to terminal memory and effector-like cells 376 (CD8.TemTerm: odds ratio = 3.2, P < 0.001, ISG.IFIT2: odds ratio = 2.5, P < 0.001, Fischer's 377 exact test; Fig. 5h, Extended Data Fig. 8a) and possessed significantly higher expression of 378 the non-viral specificity signature (P = 0.027, Wilcoxon test), suggesting tumour antigen-379 specific may be involved in MM-associated T-cell differentiation.

380

381 Tumour antigen-driven T-cell differentiation suggests a degree of tumour immunogenicity. 382 Therefore, we examined the expression of antigen-expression genes in tumour cells. T-cell 383 skewing and non-viral specificity signature expression did not correlate with tumour MHC-384 associated pathways (Extended Data Fig. 7a, 8b), possibly as these pathways reflect MHC in the context of interferon signalling²⁵. We identified *de novo* pathways enriched among each 385 386 individual patient's tumour cells (see Methods), revealing MHC and antigen processing and 387 presentation genes were frequently upregulated by individual tumours (Antigen processing 388 and presentation pathway, GSEA adjusted P < 0.1 in 6 of 16 (37.5%) of tumours tested; Fig. 389 5f, Extended Data Fig. 8c, Supplemental Table 2). Non-viral specificity signature expression was highest in patient's whose tumour cells significantly upregulated MHC pathways (P = 390 391 0.021, Wilcoxon test; Fig. 5g), suggesting the reactivity component of MM-association T-cell 392 differentiation was connected to tumour MHC class I expression and potentially antigen 393 presentation. Finally, in CoMMpass, patients whose tumours highly expressed MHC pathway 394 genes had superior outcome (P = 0.031, log-rank test; Fig. 5h), suggesting that T-cell 395 differentiation dynamics associated with high tumour MHC class I expression may influence 396 clinical outcomes.

397

398 Discussion

Recent insights into anti-tumour T-cell immunity have largely derived from studies of solid tumours but a similar understanding in haematological malignancies is lacking. Myeloma has a clinically-defined precursor disease phase lends itself to the study of how T-cell differentiation is altered with disease evolution.

403

In this study, we curated a large cohort of single-cell data across 11 studies and 234 donors
to identify myeloma-specific alterations to T-cells, which we enhanced through the analysis

406 of the TCR repertoire, the BM and PB, and tumour cell transcriptional state. This allowed us 407 to identify the specific features of tumour biology associated with T-cell differentiation in 408 myeloma, independent of natural heterogeneity attributable to tissue localisation and age. 409 We describe two patterns of myeloma-associated T-cell differentiation (Fig. 5i): (1) terminal 410 memory T-cells with features of antigen-specific differentiation and lacking viral-specificity 411 accumulate dependent on serum paraprotein and tumour MHC expression; and (2) effector 412 T-cells are enriched in highly-infiltrated marrows populated by stressed tumour cells. As 413 these two myeloma-associated T-cell subsets are clonally related (Fig. 5c-d), we suggest 414 they represent the differentiation of tumour-reactive clones accumulating alongside anti-415 tumour immunity through disease evolution (Extended Data Fig. 9).

416

417 It will be important to see if other immune subsets possess similar associations. In pursuit of418 this goal, we make our integrated data available for other researchers.

419

420 Our results resolve conflicting reports on the presence of exhausted T-cells in myeloma and 421 a poor history of checkpoint inhibition in this setting^{24,40,41}. We show exhausted T-cells are 422 not pervasively enriched in myeloma and are distinct from the more abundant activated 423 CD8+Tem cells which match previous descriptions of PD1-expressing CD8+ T-cells in healthy donors^{42,43}. The presence of these "pseudo-exhausted" cells may have led to 424 misidentification of exhausted cells in myeloma patients^{40,44}, especially given their enrichment 425 426 in the bone marrow (Fig. 2g). Additionally, we did not connect an exhaustion phenotype to 427 tumour-specificity (Fig. 4f, 5e), suggesting exhaustion-associated loss of tumour-reactive T-428 cells may not drive progression as is thought in solid tumours¹. However, activated CD8+Tem 429 may still be involved in bone marrow pathology, with cells resembling this phenotype 430 possessing negative and positive associations with the response to T-cell engager (TCE) 431 therapy in advanced MM and combination therapy in SMM, respectively^{23,45}.

432

433 We show myeloma is associated with an enrichment of terminally differentiated clonal memory T-cells. This analysis extends previous reports^{14,21,46} by demonstrating an 434 435 independence from age and showing concurrent changes to the TCR repertoire and systemic 436 T-cell compartment. These alterations are similar to T-cell immunosenescence changes seen during aging¹², meaning SMM and MM patients have prematurely aged T-cell compartments 437 438 (Fig. 3d). Exaggerated T cell aging in precursor conditions may explain the increased risk of infections in these patients⁴⁷, and impede the ability to control tumour growth, facilitating 439 440 progression. Prior immunosenescence may also predispose individuals to cancer 441 development hence present more frequently in patients⁴⁸. Additionally, this pattern of T-cell 442 differentiation could mechanistically represent anti-tumour T-cell responses. Patient-derived T-cells show evidence of tumour-reactivity in myeloma^{49,50}, specifically terminal memory 443 CD8+ phenotypes⁵¹. This supports our *in silico* evidence that tumour-reactivity may 444 contribute to myeloma-associated T-cell differentiation (Fig. 4g,h, 5e). This suggests that 445 446 effector T-cells enriched in infiltrated marrows may represent direct tumoricidal T-cell 447 responses. Repeated waves of tumour growth and T-cell control over time may give rise to 448 memory skewing (Extended Data Fig. 9), akin to successive infections giving rise to terminal memory cells through aging¹². This could explain the lack of exhausted T-cells in myeloma, 449 450 as T-cell stimulation would be intermittent (dependent on tumour growth) versus chronic, 451 suggesting factors besides T-cell-intrinsic loss of functionality drives progression. However, 452 alternative processes may drive T-cell differentiation in myeloma: inflammation, pervasive in the myeloma marrow⁵², can drive non-canonical memory T-cell differentiation⁵³. In vitro 453 454 validation of tumour-specific TCR clones and mapping their phenotype through disease 455 evolution will elucidate the role of T-cell specificity in myeloma.

456

457 As T-cell skewing tracked with disease advancement, it may identify donors at risk of early 458 progression. The ability to track this skewing in the PB makes it attractive for immune 459 prognostication (Fig. 3e). However, T-cell skewing was similar in asymptomatic SMM and 460 overt MM (Fig. 3). While this suggests functional anti-tumour responses occur in high-risk 461 precursor conditions, arguing for early intervention with T-cell-dependent immunotherapeutic 462 interventions such as T-cell engager therapy⁴⁵, it may preclude the use of T-cell skewing to 463 identify SMM patients at imminent risk of progression. Additionally, T-cell skewing was more 464 closely associated with serum paraprotein than clinical diagnosis (Extended Data Fig.7g). 465 This may have the potential to enhance existing paraprotein-based prognostication particularly in the rare subset of patients with non-secretory disease⁵⁴. Further work is needed 466 467 to explain the T-cell skewing-paraprotein association, but we note in addition to paraprotein 468 being an indicator of tumour bulk (thus, total tumour antigen burden or tumour-associated 469 inflammation) that malignant immunoglobulin-derived peptides can serve as immunogenic T-470 cell epitopes^{7,55}. The additional associations we identify between effector T-cells with marrow 471 infiltration and putative tumour-specificity with tumour antigen presentation-associated gene 472 expression may provide additional combinatorial opportunities for integrating immune and 473 clinical metrics into predictive measures of disease risk.

474

While we were unable to compare T-cells features and tumour genomic classification in our dataset, T-cell skewing was previously shown to be enhanced in hyperdiploid patients⁴⁶. Additionally, further work is needing to directly connect beneficial survival outcomes associated with tumour MHC and stress (possibly death-related) gene expression (Fig. 5h, Extended Data Fig. 2i) with T-cell differentiation and function. Finally, to understand how tumour genomics relates to T-cell differentiation, it will also be important to longitudinally profile neoantigen-reactive responses alongside tumour evolution.

482

483 Our results provide a conceptual framework for how T-cells are altered during myeloma 484 disease evolution and highlight the importance of contextualising immune heterogeneity with 485 tumour biology when using immune biomarkers in myeloma.

486

487 Acknowledgements

488 This work was funded by CRUK, the Medical Research Council, and the UCL/UCLH 489 Biomedical Research Centre. We thank members of the CARDMON, COSMOS and RADAR 490 teams, particularly Sayeh Foroughi, Ambreen Rashid and Grant Vallance, and the UCLH 491 Haematology Cancer Trials Unit. We thank all patients who participated in these studies. 492 Work at the CRUK City of London Centre Single Cell Genomics Facility and Cancer Institute 493 Genomics Translational Technology Platform was supported by the Cancer Research UK 494 (CRUK) City of London Centre Award [C7893/A26233]. We thank the International Myeloma 495 Society (IMS) for funding the presentation of this manuscript in abstract form at the 2022 and 496 2023 IMS Annual Meetings. We thank the authors of the publications whose data was re-497 analysed for this study for making their data freely available, particularly David B. Sykes, 498 Samuel S. McCachren, Madhav V. Dhodapkar, Romanos Sklavenitis-Pistofidis, Irene M. 499 Ghobrial, Ola Landgren, Gareth J. Morgan, Saad Z. Usmani, Francesco Maura and Reyka 500 Jayasinghe. We thank the Multiple Myeloma Research Foundation (MMRF), the Perelman 501 Family Foundation.

502 Methods

503

504 *Primary clinical samples*

505 Bone marrow aspirates from individuals with myeloma or precursor conditions were obtained 506 from patients included in one of four ongoing clinical trials: (1) Defining risk in smouldering 507 myeloma (SMM) for early detection of multiple myeloma (COSMOS), a multicentre, 508 observational UK study in smouldering myeloma (NCT05047107); (2) Risk-Adapted therapy 509 Directed According to Response (RADAR), a randomised phrase II/III trial in newly diagnosed 510 patients with multiple myeloma eligible for transplant (UK-MRA Myeloma XV)⁵⁶; (3) 511 Carfilzomib/Cyclophosphamide/Dexamethasone with Maintenance Carfilzomib in Untreated 512 Transplant-eligible Patients with Symptomatic MM to Evaluate the Benefit of Upfront ASCT 513 (CARDAMON), a phase II trial⁵⁷; (4) Biology of Myeloma, an observational study open to all 514 plasma cell disorder patients treated at University College London Hospitals (Research ethics 515 committee reference: 07/Q0502/17). Bone marrow aspirates from non-cancer controls were 516 collected as a by-product of routine elective orthopaedic surgery (hip or knee replacements) 517 via the UCL/ UCLH Biobank for Studying Health and Disease (Research ethics committee 518 reference: 20/YH/0088). All material was obtained after written informed consent in 519 accordance with the Declaration of Helsinki.

520 For scRNA-seq experiments, bone marrow aspirates were collected in 521 ethylenediamine-tetraacetic acid (EDTA) and processed within 24 hours of collection. Mononuclear cells (MNCs) were isolated by Ficoll Pague density gradient centrifugation. 522 523 using SepMate tubes (StemCell Technologies). Freshly isolated BM MNCs were analysed for 524 tumour infiltration by flow cytometry (LSRFortessa, 4 laser 16 color). Cells were stained with 525 the fluorochrome-conjugated antibody CD138 (PE, clone MI15, BioLegend), CD38 (PE-CY7, 526 Clone HB7, biolegend), and a fixable viability dye (eFluor 780, eBioscience). Tumour cell 527 marrow infiltration was determined as the frequency of live BM MNCs cells co-expressing

528 CD38 and CD138 as determined via manual gating (FlowJo v10, BD Biosciences) (Extended529 Data Fig. 1f).

530 For CyTOF experiments, MNCs were isolated by Ficoll Paque density gradient 531 centrifugation, using SepMate tubes (StemCell Technologies) and cryopreserved in 90% FBS 532 and 10% DMSO for long-term storage in liquid nitrogen.

533

534 scRNA-seq and scTCRseq sample and library preparation

535 For newly-generated "T cell-enriched/depleted" samples T-cells were enriched from freshly 536 isolated BM MNCs by magnetic separation using a Pan T-cell Isolation Kit and CD15 537 MicroBeads (Miltenyi Biotec). After sorting, the T-cell depleted and enriched compartments were pelleted and resuspended in 0.04% BSA in PBS at 10⁶ cells/mL and loaded onto the 538 539 Chromium Controller (10X Genomics). For newly-generated "CD8-enriched" samples T-cells 540 were enriched using the same protocol with the addition of CD4 MicroBeads (Miltenyi Biotec) 541 and only CD8-enriched samples were loaded. This generated a total of 47 libraries. All 542 samples were processed using the Chromium Next GEM Single Cell 5' Dual Index Kit (10X 543 Genomics, v2) following manufacturers protocol. T-cell and CD8-enriched samples were 544 additionally processes using the VDJ kit (10x Genomics). The libraries were sequenced by 545 Illumina NovoSeq 6000. Sequencing data was processed with CellRanger GEX and VDJ 546 (v6.0.0) using the GRCh38-2020-A and vdj_GRCh38_alts_ensembl-5.0.0 human reference 547 genomes, respectively. Across samples Cellranger GEX called a median of 6367 cells and 548 Cellranger VDJ a median proportion of 0.76 cells with product V J spanning TRA and TRB 549 pairs.

550

551 Filtering, integration, clustering, and dimensionality reduction of scRNA-seq data

552 scRNA-seq data were analysed and integrated using the python packages scanpy (1.8.2) and 553 scvi-tools (0.15.2)^{58,59}. Gene-barcode matrices for all newly-generated and re-analysed

samples were assigned unique sample-specific barcodes, merged, and subset to highquality cells for integration (minimum unique genes > 200, minimum total counts > 500, total percentage mitochondrial chromosome-encoding transcripts < 10%, total percentage transcripts encoding haemoglobin genes *HBB*, *HBA1* and *HBA2* < 20%). Cells called as doublets by the python package scrublet⁶⁰ (0.2.3) were removed. Samples with < 100 highquality cells were removed prior to integration.

For integration, we utilised single-cell variation inference (scvi)⁵⁹. A subset of 7000 560 561 highly variable genes across batches was calculated on log(x+1) normalised gene expression with the function scanpy.pp.highly_variable_genes(adata, batch_key="batch") to identify 562 genes with consistently high inter-cellular variation across different batches. Specific gene 563 groups which can vary between cells for technical (mitochondrial, representing cell stress) or 564 irrelevant biological (immunoglobin and TCR genes, representing lymphocyte clonality) 565 566 reasons were excluded from highly variable genes to prioritise clustering on phenotype-567 defining genes. The un-normalised expression of these 7000 variable genes was prepared 568 for scvi using the function scvi.model.SCVI.setup_anndata() with sample batch as the batch 569 key and sample identifier and 10x chemistry as categorical covariate keys. A scvi model was 570 then initialised with the following non-default parameters: scvi.model.SCVI(n latent=30, 571 n_layers=2, dropout_rate=0.2, gene_likelihood="nb"). These parameters (number of HVGs, 572 number of latent dimensions and hidden layers, dropout rate) were selected through a 573 parameter sweep focused on minimising batch influence on integrated latent representation 574 and retaining biological identify (data not shown). Minimisation of batch influence was 575 assessed by linear regression of latent dimensions against batch covariates as implemented 576 by scib (https://github.com/theislab/scib). The retention of biological identity was assessed 577 by analysing the separation of CD4+ and CD8+ T-cells (the median log ratio of CD4-578 expressing and CD8A-expressing cells closest to zero across clusters). This model was 579 trained for a maximum of 400*(20,000*x) epochs where x was the number of input cells.

Integration was first performed on all cells then repeated for just T-cell clusters using 5000
highly variable genes and gene_likelihood="nb" but otherwise identical parameters.

582 The latent representation of the trained scvi model was used to create a 583 neighbourhood graph using scanpy.pp.neighbors(adata, n_neighbors=10) for subsequent 584 graph-based clustering using the leiden algorithm. The size of the local neighbourhood 585 (n_neighbors=10) and Leiden clustering resolutions were selected for optimum granularity of 586 biological clusters. Analysis of the latent representation was used as input for creation of a 587 uniform manifold approximation and projection (UMAP, scanpy default parameters) or 588 Minimum-Distortion Embedding using the Python package pymde⁶¹ (0.1.15). For visualisation of a large number of cells on either UMAP or MDE, the R package scattermore (1.0) was used 589 590 to created rasterized dot plots.

591

592 Differential expression and pathway analysis of scRNA-seq data

593 Differential expression between specified conditions was performed using the R package 594 scran (1.26.2) function pairwiseTTests() between specified contrasts with batch as the 595 blocking level for each cell to model for batch effects. Genes were identified as significantly 596 differentially expressed with a false discovery rate (FDR, Benjamini and Hochberg-adjusted 597 P value) of < 0.1. Pathway analysis of differentially expressed genes was performed using the 598 R package fgsea (1.24.0) with gene set enrichment analysis of gene sets from BIOCARTA, 599 KEGG and REACTOME databases accessed via the R package msigdbr (7.5.1; Supplemental 600 Table 2).

601

602 Phenotyping gene expression clusters from scRNA-seq data

603 Cluster markers genes were calculated using log-normalised expression of all genes in a 604 study-aware fashion using the findMarkers function from the R package scran specifying 605 test.type="wilcox" and batch as the blocking level for each cell. This restricts differential

606 expression comparisons within individual sources and pools the downstream result, meaning 607 no inter-batch comparisons were performed. Marker genes were combined with supervised 608 analysis of the expression of known RNA and protein markers to phenotype clusters. Clusters characterised by expression of known stress-associated genes (for example, JUN, FOS)⁶² or 609 610 by co-expression of marker genes for independent phenotypes (for example, T and B cells) 611 were removed. For T-cell cluster phenotyping, clusters lacking expression of CD3D, CD3E and CD3G or both CD4 and CD8A were removed. De novo label prediction tools were run 612 613 with default parameters: Azimuth (https://azimuth.hubmapconsortium.org/) and Celltypst (https://www.celltypist.org/). Manually curated T-cell naïve and cytotoxicity gene signatures 614 were taken from Chu et al.⁶³. Gene sets were applied to cells using the R package UCell 615 $(2.2.0)^{76}$. 616

617

618 Differential abundance analysis of scRNA-seq data

We normalised cell type abundance following a compositional data framework⁶⁴. For each 619 620 sample, cluster counts were derived and zero values replaced by a Bayesian-multiplicative 621 replacement strategy which preserves the ratios between non-zero clusters, implemented using the R package zCompositions (1.4.0-1) function cmultRepl()⁶⁵, generating zero-imputed 622 623 pseudo-counts. The centered log-ratio (CLR) transformation was then used to transform 624 pseudo-counts relative to the geometric mean of all clusters in a given sample, implemented 625 using the R package compositions (2.0-6) function clr(). The CLR transformation thus reports cell type abundance relative to the per-sample average seeking to reduce the mutual 626 dependency of proportional data⁶⁶. 627

For samples from Stephenson et al.¹⁶, the median age of each age range was used (for example, for the 50-55 group 52.5 was used). Several donors in the dataset were sampled longitudinally, including Oetjen et al.⁶⁷ and Liu et al.¹⁵. In these cases, only the first longitudinal timepoint was analysed unless otherwise specified.

Normalised cluster abundances were used as input for a combination of interceptonly and additive regression models exploring the relationship between cluster abundance and different conditions (for example, patient group, or patient group and age) as described. Selected comparisons were also performed using a mixed-effect model with an additional random effect term (for sample, study of origin), implemented using the R package ImerTest (3.1-3) function Imer().

638

639 Unsupervised ordination of T cell composition and calculation of exaggerated T-cell aging

640 Normalised T cell cluster abundance was used as input for PCA using the R function prcomp. Exaggerated T cell aging was calculated by first constructing a linear model 641 642 examining the relationship between PC1 and age for non-cancer controls only. Next, the age 643 of cancer patients was used to predict PC1 values for each patient in this model. The 644 difference between predicted and real PC1 values (residuals) for each patient was interpreted 645 as the difference between the T cell skewing expected for each patient's versus their 646 observed T cell skewing, respectively. These residuals-derived values were termed 647 "exaggerated T cell aging". A patient was considered to have exaggerated T cell aging if their 648 values were greater than zero (or, skewing was greater than expected for their age).

649

650 scTCRseq pre-processing, clonal expansion calculation, T cell subset identification and 651 clustering

TCR paired alpha and beta clones (also termed clonotypes) were defined by CellRanger VDJ (raw_clonotype_id, clonotype_id) by matching shared V and J gene and CDR3 sequences for alpha and beta TCR chains were appended to single cells by matching barcode. For scTCRseq derived from published data, we used published clone identifiers. Clonal expansion was calculated as the abundance cells labelled with each clone identified in each sample. CD8+ and CD4+ clones were identified by aggregating expression of *CD8A*, *CD8B* and *CD8B2* or

658 CD4, respectively, across all cells for each clone. Clone subset was defined as CD4 (N cells 659 CD4 detected ≥ N cells CD8 detected), CD8 (CD8 < CD4), or double negative (DN, CD4 and 660 CD8 both zero; Extended Data Fig. 6a). Repertoire clonality was calculated among each 661 specific subset of cells (such as all T cells or CD8+ memory cells) with a minimum of 100 cells using Simpson's diversity index⁶⁸. Clusters of TCRs with similar sequence features were 662 identified within a single patient's alpha or beta chain repertoire using tordist3 (0.2.2)³⁶ using 663 default parameters. TCR clustering networks were constructed and visualised using the R 664 665 package igraph (1.4.2).

666

667 Annotation of HLA-matched viral reactivity-annotated TCR clones

668 HLA genotypes for 19 patients were derived using arcasHLA⁶⁹ ran on Cellranger output bam 669 files (possessorted_genome_bam). All 19 patients were newly-sequenced for this study and 670 therefore a combination of T cell-enriched/depleted and CD8-enriched (Extended Data 671 Fig.1a). arcasHLA was ran on every sample for each patient. HLA genotype for class I and 672 class II HLA was almost entirely identical across samples for an individual. In the rare cases 673 of two different samples possessing different HLA, both predicted genotypes were ignored.

674 Each donor's repertoire was then compared against the annotated TCR reactivity database VDJdb, IEDB and CEDAR³⁷⁻³⁹ subset to TCRs with annotated reactivity against an 675 676 epitope from a single human virus: cytomegalovirus (CMV), Epstein Bar virus (EBV), Influenza 677 A, or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). TCRs annotated as reactive against more than one human virus were also removed. The viral dataset set was 678 679 further subset to HLA-matched sequences for each patient's HLA genotype. A query TCR 680 clone was annotated as putatively viral-reactive if at least one alpha or one beta chain CDR3 sequence perfectly matched a CDR3 annotated against the same virus in the database, and 681 682 this clone's paired chain also perfected matched or possessed a highly similar CDR3 683 sequence to the same virus in the same HLA background. CDR3 similarity was performed as

described previously⁷⁰. Briefly, each TCR chain's CDR3 amino acid sequence was
deconstructed into a series of overlapping triplets. Pairwise similarity between two CDR3 was
defined as the number of shared triplets normalized to the number of triplets per comparison.

688 Identification of predicted neoantigen-reactive TCR clones

689 Paired whole exome sequencing was performed for two samples as previously described⁷¹. 690 Nonsynonymous mutations were selected and translated to peptides using a custom script 691 in R. We considered peptides of length 8, 9 or 10 amino acids which contained the altered 692 peptide as potential neoantigens. The immunoglobulin domain as excluded. Intronic 693 mutations or splice variants were not considered. Binding of these to the patient's HLA class 694 1 alleles was performed using NetMHCpan (4.1)⁷². Neoantigen binding was deemed significant if the mutant peptide bound the HLA allele with an IC50 of less than 500nm and 695 696 the wild type had an IC50 of >500nm.

All cases where the peptide-HLA (pHLA) binding criteria were satisfied were considered as potential binding partners for each TCR identified in the sample. TCR–pHLA binding was predicted using TEINet with the authors pretrained models and default settings ⁷³. The highest scoring pHLA-TCR was considered the most likely binding partner. Among all pHLA–TCR pairs, the phenotype of TCR clones with the highest prediction scores (>0.7) was analysis.

703

704 Identification of malignant plasma cell clones in scRNA-seq

Patient plasma cells were isolated from the clustering of all cells (Fig.1) and patients with < 50 plasma cells were removed. This generated 67,656 plasma cells from 46 patients with a median of 467 plasma cells each (range: 76–13,638). To identify tumour cells among plasma cells, we leveraged the clonal plasma cell origin of myeloma. First, we attached the expression of all available immunoglobin genes to each cell, after removing any gene filtered

710 performed earlier. Then, for each plasma cell, we identified the most highly expressed light 711 variable (kappa or lambda), heavy variable, and heavy constant chains. We next quantified 712 and ranked the abundance of every gene for each chain among an individual's plasma cells 713 (Extended Data Fig. 2a). Most individuals possessed a single gene for each chain which was 714 expressed by the majority of plasma cells (light variable median 95% range: 31-100%, heavy 715 constant median 96% range: 35-100%, heavy variable median 91% range: 24-100%). The 716 frequency of different light and heavy variable genes among tumour cells matched previously reported frequencies in myeloma⁷⁴, including IGHV3-30 in 3 (6.5%) and IGKV1-39 in 2 (4.3%) 717 718 patients. We inferred that clonal immunoglobulin expression corresponded to clonal plasma 719 cells and labelled any plasma cell expressing the most highly abundant gene for each chain 720 in that donor as a tumour cell. This method yielded 67,048 predicted tumour cells. Predicted 721 tumour cells uniquely co-expressed clonal immunoglobulin genes (Extended Data Fig. 2b) 722 and expressed genes characteristic of their translocation subgroups (Extended Data Fig. 723 2c)⁷⁵, suggesting they did represent malignant cells.

724

725 Transcriptional pathway analysis of tumour cells in scRNA-seq data

To analysis tumour cell transcriptomes, we scored tumour cells by a set of pan-cancer transcriptional pathways²⁵ using UCell. To compare the expression of individual pathways between patients, we calculated the abundance of cancer cells highly expressing a given pathway as the percentage of cells with expression greater than one standard deviation above the median for each patient's tumour cells.

731

732 De novo pathway enrichment in malignant cells

To identify novel sets of genes enriched in malignant relative to normal plasma cells, we first
isolated each the tumour cells from each patient in turn. Next, we performed differential
expression between each patient's tumour cells only and all other plasma cells not classified

as malignant. Differential expression was only performed between cells from the same
sequencing batch. This yielded a set of malignant-enriched genes for each patient. Pathway
analysis was then performed as described. The pathways significantly enriched among
malignant-associated genes in four or more patients were identified (Extended Data Fig.8b).

740

741 Transcriptional pathway survival analysis in CoMMpass

742 We analysed an association of transcriptional pathways with overall survival in bulk RNA sequencing samples from the CoMMpass cohort of newly-diagnosed MM patients²⁶, with 743 744 RNA sequencing data processed and normalised as described in Bauer et al.⁷⁷. We calculated the expression of each gene pathway by taking of each constituent gene in that pathway, 745 746 scaling expression between 0 and 1, and taking the average. We assessed the predictive 747 power of each pathway for overall and progression-free survival in patients using the 748 maximally selected rank statistic of the by R package maxstat (0.7-25), and analysed an 749 association between overall and progression-free survival and pathway expression above the 750 maxstat estimated cutpoint using a proportional hazards regression model using the R 751 package survival (3.5-5) with default parameters.

752

753 CyTOF antibody staining, data acquisition and data pre-processing

754 Details on antibodies are listed in Table S4. Conjugation of the purified antibodies with metal 755 reporters was performed with the MaxPar X8 and MaxPar MCP9 antibody labelling kits (Fluidigm Sciences) according to the manufacturer's instructions. Frozen bone marrow MNCs 756 757 or the CD138-negative populations were thawed rapidly at 37°C and resuspended into pre 758 warmed thawing media of RPMI (Sigma-Aldrich) containing 20% FBS, 2mM EDTA 759 (pluriSelect) and 5mg DNase (Sigma-Aldrich). Cell suspensions were washes and filtered to form a single cell suspension. Cells were incubated with 5µM Cell-ID Cisplatin (Fluidigm 760 Sciences) in serum free RPMI for 3 minutes at room temperature (rT) to identify dead cells. 761

762 Cells were then washes and incubated with human Fc block (BioLegend) for 10 minutes at 763 rT before being barcoded using a 6-choose-3 Cadmium CD45 Live Barcoding (Fluidigm 764 Sciences). All samples were stained in the same batch. After live cell barcoding, the combined 765 samples were then stained with metal-conjugated antibodies for surface antigens for 30 766 minutes at rT. After staining, cells were washed with MaxPar Cell Staining Buffer and 767 permeabilised with MaxPar nuclear antigen staining buffer before staining with metal-768 conjugated antibodies for intracellular antigens. Cells were again washed and fixed using 769 1.6% paraformaldehyde. Cells were then incubated with Cell-ID intercalator-Ir (Fluidigm 770 Sciences) to stain all cells in MaxPar Fix and Perm Buffer (Fluidigm Sciences) and aliguoted 771 and frozen in cryovials. Stained samples were thawed and washed on the day of acquisition.

Cells were acquired on the Helios mass cytometer (Fluidigm Sciences). Data from different days were normalized by using EQ Four Element Calibration Beads (Fluidigm Sciences). Data was debarcoded using the Fluidigm CyTOF software and patient sample fcs files run from different days were concatenated. Before downstream analysis, initial data clean up was carried out using FlowJo. Live CD3+ cells were exported by manual gating on Event_length, Residual, Offset, DNA (¹⁹¹Ir and ¹⁹³Ir), live cells (¹⁹⁵Ir) and CD3 expression (⁸⁹Y).

778

779 Downstream analysis of CyTOF data

780 CyTOF data were analysed using a custom R pipeline modified from Nowicka et al.⁷⁸.

Protein expression data was normalised using the flowCore (2.10.0) logicleTransform() function. Cells were clustered using T-cell markers (all unique proteins shown in Extended Data Fig. 4) using FlowSOM (2.6.0) on a 12 x 12 node self-organising map. This generated 50 putative T-cell clusters. Only clusters expressing CD3 and either CD4 or CD8 were taken retained. One cluster strongly co-expressing all markers was removed as a likely artifact. The remaining clusters were merged to 17 final clusters based on homogeneous co-expression of known T-cell marker genes (for example, CD8+CD45RA+CD45RO-IL7R+TCF7+ were

classified as naïve CD8+ T-cells). The expression of T-cell marker proteins for 1000 cells persample was used to calculate a UMAP using the R package uwot (0.1.14) with the following
parameters umap(expression, n_neighbors=25, metric="cosine", spread=2, min_dist=0.1,
fast_sgd=TRUE) based on visual separation of clusters.

792

793 Comparison of T-cell clusters across scRNA-seq and CyTOF

794 First, T cell markers shared between the scRNA-seq and CyTOF datasets were identified. These included (protein/RNA) TBET/TBX21, FOXP3/FOXP3, "TOX/TOX, LAG3/LAG3, 795 796 CTLA4/CTLA4, KLRG1/KLRG1, PD1/PDCD1, EOMES/EOMES, CD28/CD28, TCF1/TCF7, CD69/CD69, CD4/CD4, CD8/CD8A, ICOS/ICOS, IL7R/IL7R, TIGIT/TIGIT, CD25/IL2RA, 797 KI67/MKI67, GZMB/GZMB, HLA-DR/HLA-DRA. We also restricted our analysis to scRNA-798 799 seq clusters likely to be profiled using our existing CyTOF panel. Therefore, we removed the 800 interferon-expressing ISG.ISG15 and Teff.IFIT2 and invariant MAIT_gdT scRNA-seq clusters. 801 Additionally, we removed the proliferating T cell (Prolif.) scRNA-seg cluster, to avoid a 802 confusion when comparing to the CyTOF CD4.Tm-Prolif. and CD8.Tem-Prolif. clusters, which 803 were also removed. The average expression of each shared marker was scaled within 804 scRNA-seg or CyTOF clusters. The correlation between each cluster's shared markers was 805 calculated using Pearson correlation (Extended Data Fig.4d-e), with highly correlated clusters 806 inferred to represent the same underlying T cell phenotype.

807

808 Statistical analyses

For comparison of means in box plots, *P* values were calculated by two-sided Wilcoxon test using the R package ggpubr (0.6.0). R and *P* values for correlations were calculated by Pearson correlation. For hierarchal clustering on heatmaps, Euclidean distance was used as the default distance measure.

813

814 Data availability

815 Published datasets were acquired following the instructions in each original publication. 816 Specifically, data shared through the gene expression omnibus (GEO) can be accessed for 817 Maura et al. under accession GSE161195, Bailur et al. under accession GSE163278, Oetjen et al. under accession GSE120221, Granja et al. under accession GSE139369, Zavidij et al. 818 819 under accession GSE124310, Kfoury et al. under accession GSE143791, and Zheng et al. 820 under accession GSE156728. Data shared via dbGaP for Sklavenitis-Pistofidis et al. can be 821 accessed under accession phs002476.v1.p1. Data shared online can be accessed for 822 Stephenson et al. (via https://covid19cellatlas.org/), Conde et al. (via https://www.tissueimmunecellatlas.org/), 823 and Liu et al. (via 824 https://explore.data.humancellatlas.org/projects/2ad191cd-bd7a-409b-9bd1-825 e72b5e4cce81). The integrated single-cell RNA and TCR datasets and cohort information are available online (https://zenodo.org/doi/10.5281/zenodo.11047959). CoMMpass data were 826 827 downloaded from the MMRF researcher gateway (https://research.themmrf.org). Newly-828 generated raw sequencing data will be made publicly available and uploaded to the GEO 829 upon peer-reviewed publication. Code to reproduce figures will be made available upon peer-

reviewed publication or upon reasonable request.

831

832 Supplemental tables

- 833 Supplemental Table 1. Overview of donors included in single-cell RNA sequencing cohort.
- 834 Supplemental Table 2. Constituent genes for gene sets and pathways used throughout this
- 835 study.
- 836 Supplemental Table 3. Significantly differential expressed marker genes for T-cell clusters.
- 837 Supplemental Table 4. Information regarding CyTOF panel.
- 838 Supplemental Table 5. Differential expression results between clones with and without
- 839 putative viral-specificity annotations.
- 840

841 References 842 1. de Visser, K. E. & Joyce, J. A. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. 843 Cancer Cell 41, 374-403 (2023). 844 Philip, M. & Schietinger, A. CD8+ T cell differentiation and dysfunction in cancer. Nat. Rev. Immunol. 2021 224 22, 2. 845 209-223 (2021). 846 З. Reading, J. L. et al. The function and dysfunction of memory CD8+ T cells in tumor immunity. Immunological Reviews 847 vol. 283 194-212 (2018). 848 Kay Chung, H., McDonald, B. & Kaech, S. M. The architectural design of CD8+ T cell responses in acute and chronic 4. 849 infection: Parallel structures with divergent fates. J. Exp. Med. 218, (2021). 850 5. Blank, C. U. et al. Defining 'T cell exhaustion'. Nat. Rev. Immunol. 19, 665-674 (2019). 851 6. Chow, A., Perica, K., Klebanoff, C. A. & Wolchok, J. D. Clinical implications of T cell exhaustion for cancer 852 immunotherapy. Nat. Rev. Clin. Oncol. 2022 1912 19, 775-790 (2022). 853 7. van de Donk, N. W. C. J., Pawlyn, C. & Yong, K. L. Multiple myeloma. The Lancet vol. 397 410-427 (2021). 854 8. Bazarbachi, A. H., Al Hamed, R., Malard, F., Harousseau, J. L. & Mohty, M. Relapsed refractory multiple myeloma: a 855 comprehensive overview. Leukemia 33, 2343-2357 (2019). 856 9. Mateos, M. V. et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma 857 (SMM). Blood Cancer J. 2020 1010 10, 1-11 (2020). 858 Landgren, O. et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple 10. 859 myeloma: A prospective study. Blood 113, 5412-5417 (2009). 860 11. Ho, M. et al. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined 861 significance (MGUS) and smoldering multiple myeloma (SMM). Leuk. 2020 3412 34, 3111-3125 (2020). 862 12. Mogilenko, D. A., Shchukina, I. & Artyomov, M. N. Immune ageing at single-cell resolution. Nat. Rev. Immunol. 2021 863 228 22, 484-498 (2021). 864 13. Di Rosa, F. Maintenance of memory T cells in the bone marrow: survival or homeostatic proliferation? Nat. Rev. 865 Immunol. 2016 164 16, 271-271 (2016). 866 14. Bailur, J. K. et al. Early alterations in stem-like/marrow-resident T cells and innate and myeloid cells in preneoplastic 867 gammopathy. JCI Insight 4, (2019). 868 15. Liu, R. et al. Co-evolution of tumor and immune cells during progression of multiple myeloma. Nat. Commun. 2021 869 *121* **12**, 1–18 (2021). 870 16. Stephenson, E. et al. Single-cell multi-omics analysis of the immune response in COVID-19. Nat. Med. 2021 275 27, 871 904-916 (2021). 872 17. Domínguez Conde, C. et al. Cross-tissue immune cell analysis reveals tissue-specific features in humans. Science 873 (80-.). 376, (2022). 874 18. Oetjen, K. A. et al. Human bone marrow assessment by single-cell RNA sequencing, mass cytometry, and flow 875 cytometry. JCI Insight 3, (2018). 876 Maura, F. et al. Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma 19. 877 treated with immunotherapy regimens. Nat. Cancer 2023 412 4, 1660-1674 (2023). 878 20. Granja, J. M. et al. Single-cell multiomic analysis identifies regulatory programs in mixed-phenotype acute leukemia. 879 Nat. Biotechnol. 2019 3712 37, 1458-1465 (2019). 880 21. Zavidij, O. et al. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of 881 multiple myeloma. Nat. Cancer 1, 493-506 (2020). 882 22. Kfoury, Y. et al. Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment. 883 Cancer Cell 39, 1464-1478.e8 (2021). 884 23. Sklavenitis-Pistofidis, R. et al. Immune biomarkers of response to immunotherapy in patients with high-risk 885 smoldering myeloma. Cancer Cell 40, 1358-1373.e8 (2022). 886 24. Zheng, L. et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells. Science (80-.). 374, (2021).

887 25. Gavish, A. *et al.* Hallmarks of transcriptional intratumour heterogeneity across a thousand tumours. *Nat. 2023*

888		6187965 618 , 598–606 (2023).
889	26.	Skerget, S. et al. Genomic Basis of Multiple Myeloma Subtypes from the MMRF CoMMpass Study. medRxiv
890		2021.08.02.21261211 (2021) doi:10.1101/2021.08.02.21261211.
891	27.	Nutt, S. L., Hodgkin, P. D., Tarlinton, D. M. & Corcoran, L. M. The generation of antibody-secreting plasma cells. Nat.
892		<i>Rev. Immunol.</i> 15 , 160–171 (2015).
893	28.	Szabo, P. A. et al. Single-cell transcriptomics of human T cells reveals tissue and activation signatures in health and
894		disease. Nat. Commun. 10, 1–16 (2019).
895	29.	Ren, X. et al. Insights Gained from Single-Cell Analysis of Immune Cells in the Tumor Microenvironment.
896		https://doi.org/10.1146/annurev-immunol-110519-071134 39 , 583–609 (2021).
897	30.	Cano-Gamez, E. et al. Single-cell transcriptomics identifies an effectorness gradient shaping the response of CD4+ T
898		cells to cvtokines. <i>Nat. Commun. 2020 111</i> 11 . 1–15 (2020).
899	31.	Kared, H., Martelli, S., Ng, T. P., Pender, S. L. F. & Larbi, A. CD57 in human natural killer cells and T-lymphocytes.
900		Cancer Immunol, Immunother, 65 , 441–452 (2016).
901	32	Omilusik K D et al. Transcriptional repressor ZEB2 promotes terminal differentiation of CD8+ effector and memory
902	02.	T cell populations during infection <i>L</i> Exp. Med. 212 , 2027–2039 (2015)
902	33	Khan O et al. TOX transcriptionally and epigenetically programs CD8. T cell exhaustion Nat. 2019 5717764 571
000 001	55.	
904 005	04	211-216 (2019).
900	34. 05	Greipp, P. R. et al. International staging system for multiple myeloma. J. Clin. Oncol. 23, 3412–3420 (2005).
900	35.	Pauken, K. E. et al. TCR-sequencing in cancer and autoimmunity: barcodes and beyond. Trends Immunol. 43, 180-
907		
908	36.	Dash, P. et al. Quantifiable predictive features define epitope specific 1 cell receptor repertoires. Nature 547, 89
909	07	
910	37.	Bagaev, D. V. et al. VDJdb in 2019: database extension, new analysis infrastructure and a 1-cell receptor motif
911		compendium. Nucleic Acids Res. 48, D1057–D1062 (2020).
912	38.	Fleri, W. et al. The immune epitope database and analysis resource in epitope discovery and synthetic vaccine
913		design. Front. Immunol. 8, 250318 (2017).
914	39.	Koşaloğlu-Yalçın, Z. et al. The Cancer Epitope Database and Analysis Resource (CEDAR). Nucleic Acids Res. 51,
915		D845–D852 (2023).
916	40.	Kourelis, T. V. et al. Mass cytometry dissects T cell heterogeneity in the immune tumor microenvironment of common
917		dysproteinemias at diagnosis and after first line therapies. Blood Cancer J. 9, (2019).
918	41.	Meermeier, E. W., Bergsagel, P. L. & Chesi, M. Next-Generation Therapies for Multiple Myeloma. Annu. Rev. Cancer
919		Biol. 8 , (2024).
920	42.	Galletti, G. et al. Two subsets of stem-like CD8+ memory T cell progenitors with distinct fate commitments in
921		humans. Nat. Immunol. 2020 2112 21, 1552–1562 (2020).
922	43.	Mogilenko, D. A. et al. Comprehensive Profiling of an Aging Immune System Reveals Clonal GZMK+ CD8+ T Cells as
923		Conserved Hallmark of Inflammaging. Immunity 54, 99-115.e12 (2021).
924	44.	Hudson, W. H. & Wieland, A. Technology meets TILs: Deciphering T cell function in the -omics era. Cancer Cell 41,
925		41–57 (2023).
926	45.	Friedrich, M. J. et al. The pre-existing T cell landscape determines the response to bispecific T cell engagers in
927		multiple myeloma patients. Cancer Cell (2023) doi:10.1016/J.CCELL.2023.02.008.
928	46.	Dang, M. et al. Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease. Cancer
929		<i>Cell</i> 41 , 1032-1047.e4 (2023).
930	47.	Ludwig, H., Meckl, A. & Engelhardt, M. Compliance with vaccination recommendations among patients with multiple
931		myeloma: A real world experience. HemaSphere (2021) doi:10.1097/HS9.0000000000000597.
932	48.	Lian, J., Yue, Y., Yu, W. & Zhang, Y. Immunosenescence: a key player in cancer development. J. Hematol. Oncol.
933		<i>2020 131</i> 13 , 1–18 (2020).
934	49.	Noonan, K. et al. Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic
935		precursors. Cancer Res. 65, 2026–2034 (2005).

936 50. Spisek, R. et al. Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with 937 monoclonal gammopathy. J. Exp. Med. 204, 831 (2007). 938 51. Vuckovic, S. et al. Inverse relationship between oligoclonal expanded CD69- TTE and CD69+ TTE cells in bone 939 marrow of multiple myeloma patients. Blood Adv. 4, 4593-4604 (2020). 940 52. de Jong, M. M. E. et al. The multiple myeloma microenvironment is defined by an inflammatory stromal cell 941 landscape. Nat. Immunol. 2021 226 22, 769-780 (2021). 942 53. Henson, S. M. & Akbar, A. N. Memory T-cell homeostasis and senescence during aging. Adv. Exp. Med. Biol. 684, 943 189-197 (2010). 944 54. Zamir, I. et al. Multiple Myeloma Oligosecretory Relapse, a Non-Negligible Phenomenon. Frequency, Clinical 945 Characteristics and Outcomes in a Single Center. Blood 138, 3772-3772 (2021). 946 55. Trojan, A. et al. Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly 947 expressed in B-cell malignancies. Nat. Med. 2000 66 6, 667-672 (2000). 948 56. Royle, K. L. et al. Risk and response adapted therapy following autologous stem cell transplant in patients with newly 949 diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised 950 controlled trial. BMJ Open 12, (2022). 951 57. Yong, K. et al. Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-952 dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in 953 England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial. Lancet. Haematol. 10, e93-e106 954 (2023). 955 58. Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: Large-scale single-cell gene expression data analysis. Genome Biol. 956 **19**, 1–5 (2018). 957 Gayoso, A. et al. A Python library for probabilistic analysis of single-cell omics data. Nat. Biotechnol. 2022 402 40, 59. 958 163-166 (2022). 959 60. Wolock, S. L., Lopez, R. & Klein, A. M. Scrublet: Computational Identification of Cell Doublets in Single-Cell 960 Transcriptomic Data. Cell Syst. 8, 281-291.e9 (2019). 961 61. Agrawal, A., Ali, A. & Boyd, S. Minimum-Distortion Embedding. Found. Trends Mach. Learn. 14, 211–378 (2021). 962 62. Araúzo-Bravo, M. J., Izeta, A. & Ascensión, A. M. The need to reassess single-cell RNA sequencing datasets: the 963 importance of biological sample processing. F1000Research 10, (2021). 964 63. Chu, Y. et al. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance. Nat. Med. 965 2023 296 29, 1550-1562 (2023). 966 64. Quinn, T. P. et al. A field guide for the compositional analysis of any-omics data. Gigascience 8, 1-14 (2019). 967 65. Palarea-Albaladejo, J. & Martín-Fernández, J. A. zCompositions - R package for multivariate imputation of left-968 censored data under a compositional approach. Chemom. Intell. Lab. Syst. 143, 85-96 (2015). 969 Aitchison, J. The Statistical Analysis of Compositional Data. J. R. Stat. Soc. Ser. B 44, 139-160 (1982). 66. 970 67. Oetjen, K. A. et al. Human bone marrow assessment by single-cell RNA sequencing, mass cytometry, and flow 971 cytometry. JCI insight 3, (2018). 972 68. Simpson, E. H. Measurement of diversity [16]. Nature 163, 688 (1949). 973 69. Orenbuch, R. et al. arcasHLA: high-resolution HLA typing from RNAseq. Bioinformatics 36, 33-40 (2020). 974 70. Joshi, K. et al. Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer. 975 Nat. Med. 2019 2510 25, 1549-1559 (2019). 976 71. Walker, I. G. et al. Machine learning from the CARDAMON trial identifies a carfilzomib-specific mutational response 977 signature. medRxiv 2023.04.08.23288287 (2023) doi:10.1101/2023.04.08.23288287. 978 72. Reynisson, B., Alvarez, B., Paul, S., Peters, B. & Nielsen, M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved 979 predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand 980 data. Nucleic Acids Res. 48, W449-W454 (2020). 981 Jiang, Y., Huo, M. & Li, S. C. TEINet: a deep learning framework for prediction of TCR-epitope binding specificity. 73. 982 Brief. Bioinform. 24, 1-10 (2023).

983 74. González, D. et al. Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood 110,

984		3112–3121 (2007).
985	75.	Kaiser, M. F. et al. A TC classification-based predictor for multiple myeloma using multiplexed real-time quantitative
986		PCR. Leuk. 2013 278 27, 1754–1757 (2013).
987	76.	Andreatta, M. & Carmona, S. J. UCell: Robust and scalable single-cell gene signature scoring. Comput. Struct.
988		Biotechnol. J. 19, 3796–3798 (2021).
989	77.	Rasche, L. et al. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat.
990		Commun. 8 , (2017).
991	78.	Nowicka, M. et al. CyTOF workflow: differential discovery in high-throughput high-dimensional cytometry datasets.
992		F1000Research 2019 6748 6 , 748 (2019).
993		
994		